Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Lancet

• Publication date

  2015-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(14)62115-2PMID 25743173
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

  2015cited by this paper
• Microsomal transfer protein (MTP) inhibition—a novel approach to the treatment of homozygous hypercholesterolemia

  2014cited by this paper
• Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study.

  2014cited by this paper
• Effects of extended-release niacin with laropiprant in high-risk patients.

  2014cited by this paper
• Efficacy and safety of mipomersen sodium (Kynamro)

  2013cited by this paper
• Diagnosis and treatment of familial hypercholesterolaemia.

  2013cited by this paper
• Effects of dalcetrapib in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

  2012cited by this paper
• Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

  2012cited by this paper
• Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants.

  2012cited by this paper
• Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

  2012cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2011cited by this paper
• Lapaquistat Acetate: Development of a Squalene Synthase Inhibitor for the Treatment of Hypercholesterolemia

  2011cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

  2010cited by this paper
• ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.

  2009cited by this paper
• Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials

  2008cited by this paper
• Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

  2008cited by this paper
• Simvastatin with or without ezetimibe in familial hypercholesterolemia.

  2008cited by this paper
• Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

  2008cited by this paper
• [Commentary to the article: Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43 ].

  2008cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

  2007cited by this paper
• Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

  2007cited by this paper
• Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).

  2002cited by this paper
• Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.

  2001cited by this paper
• Cholesteryl ester transfer protein, high density lipoprotein and arterial disease

  2001cited by this paper
• A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

  2000cited by this paper
• Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia.

  1986cited by this paper
• Abortions because of unavailability of prenatal diagnosis.

  1981cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?

  2026cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors: State of the Science

  2026cites this paper
• Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta‐Analysis of Randomized Controlled Trials

  2025cites this paper
• Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy

  2024cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

  2024cites this paper
• Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?

  2024cites this paper
• Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia.

  2024cites this paper
• Recent advances in the management and implementation of care for familial hypercholesterolaemia.

  2023cites this paper
• CETP Inhibitors: Should We Continue to Pursue This Pathway?

  2022cites this paper
• Can we revive CETP-inhibitors for the prevention of cardiovascular disease?

  2022cites this paper
• Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia

  2021cites this paper
• Familial Hypercholesterolemia: JACC Focus Seminar 4/4.

  2021cites this paper
• Lipoprotein (a): When to Measure and How to Treat?

  2021cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2020cites this paper
• The mystery of evacetrapib - why are CETP inhibitors failing?

  2020cites this paper
• Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events

  2019cites this paper
• Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report

  2019cites this paper
• Enhancement of HDL by Policosanol

  2019cites this paper
• Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis

  2019cites this paper
• Biology, pathophysiology and current therapies that affect lipoprotein (a) levels.

  2019cites this paper
• Latest Updates on Lipid Management

  2019cites this paper
• Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?

  2019cites this paper
• Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?

  2018cites this paper
• Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.

  2018cites this paper
• Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management

  2018cites this paper
• Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents

  2018cites this paper
• Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects

  2018cites this paper
• The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis

  2018cites this paper
• Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review

  2018cites this paper
• Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk – are major benefits REVEALed?

  2018cites this paper
• Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

  2018cites this paper
• Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia

  2018cites this paper
• Present therapeutic role of cholesteryl ester transfer protein inhibitors

  2018cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors

  2017cites this paper
• A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

  2017cites this paper
• Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.

  2017cites this paper
• Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future

  2017cites this paper
• Drugs for rare disorders

  2017cites this paper
• Hyperlipoproteinaemia(a) – apheresis and emerging therapies

  2017cites this paper
• The renaissance of lipoprotein(a): Brave new world for preventive cardiology?

  2017cites this paper
• Investigational therapies for hypercholesterolemia

  2017cites this paper
• Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects

  2017cites this paper
• Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing.

  2017cites this paper
• Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

  2017cites this paper
• Assessment of pharmacokinetics, bioavailability and protein binding of anacetrapib in rats by a simple high-performance liquid chromatography-tandem mass spectrometry method.

  2017cites this paper
• Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

  2017cites this paper
• Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

  2017cites this paper
• Novel treatment options for the management of heterozygous familial hypercholesterolemia

  2017influential citation
• Lipoprotein(a)-apheresis in the light of new drug developments.

  2017cites this paper
• New Drugs for Atherosclerosis.

  2017cites this paper
• Anacetrapib as a potential cardioprotective strategy

  2017cites this paper
• Measuring the effects of CVD interventions and studies across socioeconomic groups: A brief review.

  2017cites this paper
• Potential Lipid-Lowering Mechanisms of Biochanin A.

  2017cites this paper
• Pharmacological management of diabetic dyslipidemia

  2017cites this paper
• Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors

  2017cites this paper
• Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits

  2017cites this paper
• Advances in Hypercholesterolemia

  2017cites this paper
• Importancia de la medicina traslacional: mecanismos del beneficio del tratamiento de las dislipemias y su implicación en la reducción de la placa

  2017cites this paper
• Therapies Targeting HDLc Levels and HDL Function

  2017cites this paper
• Case Histories: Anacetrapib

  2017cites this paper
• AGBL 4 , PRL 8 and PCSK 9 genetic variants and their interactions on dyslipidemia

  2017cites this paper
• Atherothrombose

  2017cites this paper
• Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia

  2017cites this paper
• Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

  2017cites this paper
• Enhancement of High-Density Lipoprotein Cholesterol Functions by Encapsulation of Policosanol Exerts Anti-Senescence and Tissue Regeneration Effects Via Improvement of Anti-Glycation, Anti-Apoptosis, and Cholesteryl Ester Transfer Inhibition

  2016cites this paper
• Current and future trends in the lipid lowering therapy

  2016cites this paper
• Viejos y nuevos hipolipemiantes

  2016cites this paper
• Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia

  2016cites this paper
• Cholesteryl ester transfer protein inhibitors: challenges and perspectives

  2016influential citation
• Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk

  2016cites this paper
• From Lipids to Inflammation : New Approaches to Reducing Atherosclerotic Risk

  2016cites this paper
• Novel Therapies for Familial Hypercholesterolemia

  2016cites this paper
• Genetic variants in CETP increase risk of intracerebral hemorrhage

  2016cites this paper
• Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

  2016cites this paper
• Clinical trials with cholesteryl ester transfer protein inhibitors

  2016cites this paper
• Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease

  2016cites this paper
• Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.

  2016cites this paper
• From Lipids to Inflammation

  2016cites this paper
• Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease

  2016cites this paper
• Recent advances in the pharmacological management of hypercholesterolaemia.

  2016cites this paper
• Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.

  2016cites this paper
• From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.

  2016cites this paper
• Relation between plasma and brain lipids

  2016cites this paper
• Effects of the mediterranean diet and virgin olive oil on the function of high-density lipoproteins and the atherogenicity of low-density lipoproteins in humans

  2016cites this paper
• The extended phenotype of familial hypercholesterolemia

  2016cites this paper
• Lipid lowering for primary prevention of stroke in older adults?

  2015cites this paper
• Statins and Mipomersen: Mechanisms of Action and Patient Tolerability

  2015cites this paper
• Statins and CETP Inhibitors: Anacetrapib and Evacetrapib: The Last Hope?

  2015cites this paper
• Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future

  2015cites this paper
• Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.

  2015cites this paper
• Novel therapeutics in hypertriglyceridemia

  2015cites this paper
• New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.

  2015cites this paper
• [Importance of dyslipidaemia in cardiovascular disease: a point of view].

  2015cites this paper
• New Approaches in Detection and Treatment of Familial Hypercholesterolemia

  2015cites this paper
• Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014).

  2015cites this paper
• Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes.

  2015cites this paper
• Anacetrapib in familial hypercholesterolaemia: pros and cons.

  2015cites this paper
• Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?

  2015cites this paper
• Lipids, blood pressure and kidney update 2015

  2015cites this paper
• Cholesteryl ester transfer protein: ace of spades, queen of hearts, or the joker?

  2015cites this paper